# A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors

> **NCT01603979** · PHASE1 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **BIOLOGICAL:** AV-203

## Key facts

- **NCT ID:** NCT01603979
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603979, "A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01603979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*